Company news

Apellis Pharmaceuticals, Inc. news in 2022

Apellis Pharmaceuticals, Inc.'s news releases, calls and decks from 2022, newest first.

View company

Apellis Submits Marketing Authorization Application to the European Medicines Agency for Pegcetacoplan for Geographic Atrophy

December 15, 2022

Apellis Announces FDA Acceptance of NDA Amendment and New PDUFA Date of February 26, 2023 for Pegcetacoplan for Geographic Atrophy (GA)

November 17, 2022

Apellis Pharmaceuticals Reports Third Quarter 2022 Financial Results

November 6, 2022

Apellis to Present New Long-Term Data Reinforcing the Robust Efficacy and Safety Profile of EMPAVELI® (pegcetacoplan) in PNH Patients at 2022 ASH Annual Meeting

November 2, 2022

Apellis Announces Plans to Submit 24-Month Phase 3 Data to the FDA for Pegcetacoplan NDA for Geographic Atrophy (GA)

November 2, 2022

Apellis Pharmaceuticals to Host Conference Call on Nov 7, 2022 to Discuss Third Quarter 2022 Financial Results

October 30, 2022

Apellis Announces Four Oral Presentations of Data from the Phase 3 DERBY and OAKS Studies of Pegcetacoplan in Geographic Atrophy (GA) to be Presented at the American Academy of Ophthalmology Annual Meeting

September 29, 2022

Apellis Announces 24-Month Phase 3 Post Hoc Results Showing Treatment with Pegcetacoplan Led to Preservation of Function in High-Risk Areas of the Retina in Patients with Geographic Atrophy (GA) at AAO Annual Meeting

September 29, 2022

Apellis Pharmaceuticals Announces New Presentation Time at the Bank of America Global Healthcare Conference

September 11, 2022

Apellis Announces 24-Month Results Showing Increased Effects Over Time with Pegcetacoplan in Phase 3 DERBY and OAKS Studies in Geographic Atrophy (GA)

August 23, 2022

Apellis Pharmaceuticals Reports Second Quarter 2022 Financial Results

August 7, 2022

Apellis Pharmaceuticals to Host Conference Call on Aug 8, 2022 to Discuss Second Quarter 2022 Financial Results

July 31, 2022

Apellis Announces Agreements to Exchange Approximately $75.6 Million in Principal Amount of Its 3.500% Convertible Senior Notes Due 2026 for Common Stock

July 26, 2022

Apellis Announces FDA Acceptance and Priority Review of the New Drug Application for Pegcetacoplan for the Treatment of Geographic Atrophy (GA)

July 18, 2022

Apellis Announces Five Oral Presentations in Geographic Atrophy (GA) Highlighted at the ASRS Annual Scientific Meeting

July 13, 2022

Apellis Expands R&D Collaboration with Affilogic to Develop Targeted Complement Therapies for Delivery into the Brain

June 21, 2022

Apellis and Sobi Report New Data Reinforcing the Robust Efficacy and Safety Profile of EMPAVELI® (pegcetacoplan) for PNH at EHA 2022 Congress

June 9, 2022

Apellis and Sobi Announce First Patient Dosed in Phase 3 VALIANT Study of Pegcetacoplan for IC-MPGN and C3G, Rare Kidney Diseases with High Unmet Medical Need

June 6, 2022

Apellis Announces Submission of New Drug Application to the FDA for Pegcetacoplan for Geographic Atrophy

May 31, 2022

Apellis Announces Seven Abstracts in PNH to be Presented at the European Hematology Association Congress

May 11, 2022

Apellis Pharmaceuticals to Present at the Bank of America Securities 2022 Healthcare Conference

May 4, 2022

Apellis Pharmaceuticals Reports First Quarter 2022 Financial Results

May 3, 2022

Apellis Announces Dr. Peter Hillmen, Renowned Hematologist and PNH Expert, to Join Company

May 2, 2022

Apellis Announces Detailed 18-Month Results from Phase 3 DERBY and OAKS Studies of Pegcetacoplan for Geographic Atrophy (GA) at ARVO Annual Meeting

May 1, 2022

Apellis Pharmaceuticals to Host Conference Call on May 4, 2022 to Discuss First Quarter 2022 Financial Results

April 25, 2022

Apellis Announces Results from New Global Survey Conducted by The Harris Poll Revealing the Emotional Burden and Impact on Independence Caused by Geographic Atrophy (GA)

April 20, 2022

Apellis Pharmaceuticals to Present at the 21st Annual Needham Virtual Healthcare Conference

April 3, 2022

Apellis Pharmaceuticals Announces Closing of Public Offering of Common Stock and Full Exercise of Option to Purchase Additional Shares

March 27, 2022

Apellis Pharmaceuticals Announces Pricing of Public Offering of Common Stock

March 23, 2022

Apellis Pharmaceuticals Announces Proposed Public Offering of Common Stock

March 22, 2022

Apellis Announces Pegcetacoplan Showed Continuous and Clinically Meaningful Effects at Month 18 in Phase 3 DERBY and OAKS Studies for Geographic Atrophy (GA)

March 15, 2022

Apellis Pharmaceuticals Reports Fourth Quarter and Full Year 2021 Financial Results

February 27, 2022

Apellis Pharmaceuticals to Host Conference Call on February 28, 2022 to Discuss Fourth Quarter and Full Year 2021 Financial Results

February 21, 2022

Apellis Pharmaceuticals to Present at the 40th Annual J.P. Morgan Healthcare Conference

January 2, 2022

Calls in 2022